US20110263638A1 - Therapeutic agent for glaucoma comprising rho kinase inhibitor and ß- blocker - Google Patents
Therapeutic agent for glaucoma comprising rho kinase inhibitor and ß- blocker Download PDFInfo
- Publication number
- US20110263638A1 US20110263638A1 US13/135,295 US201113135295A US2011263638A1 US 20110263638 A1 US20110263638 A1 US 20110263638A1 US 201113135295 A US201113135295 A US 201113135295A US 2011263638 A1 US2011263638 A1 US 2011263638A1
- Authority
- US
- United States
- Prior art keywords
- rho kinase
- blocker
- kinase inhibitor
- glaucoma
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003590 rho kinase inhibitor Substances 0.000 title claims abstract description 67
- 239000002876 beta blocker Substances 0.000 title claims abstract description 58
- 229940097320 beta blocking agent Drugs 0.000 title claims abstract description 58
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 15
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960004374 befunolol Drugs 0.000 claims abstract description 9
- ZPQPDBIHYCBNIG-UHFFFAOYSA-N befunolol Chemical group CC(C)NCC(O)COC1=CC=CC2=C1OC(C(C)=O)=C2 ZPQPDBIHYCBNIG-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960004324 betaxolol Drugs 0.000 claims abstract description 9
- 229960001222 carteolol Drugs 0.000 claims abstract description 9
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960000831 levobunolol Drugs 0.000 claims abstract description 9
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims abstract description 9
- 229960002704 metipranolol Drugs 0.000 claims abstract description 9
- 229950000754 nipradilol Drugs 0.000 claims abstract description 9
- JTVBXQAYBIJXRP-SNVBAGLBSA-N 4-[(1R)-1-aminoethyl]-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)benzamide Chemical group C1=CC([C@H](N)C)=CC=C1C(=O)NC1=CC=NC2=C1C=CN2 JTVBXQAYBIJXRP-SNVBAGLBSA-N 0.000 claims abstract description 6
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 claims abstract 4
- BQIPXWYNLPYNHW-UHFFFAOYSA-N metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 claims abstract 4
- 230000004410 intraocular pressure Effects 0.000 description 23
- 239000000243 solution Substances 0.000 description 19
- 230000009471 action Effects 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- 230000001603 reducing effect Effects 0.000 description 13
- 238000009472 formulation Methods 0.000 description 11
- 210000001508 eye Anatomy 0.000 description 8
- 239000002997 ophthalmic solution Substances 0.000 description 8
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229960004605 timolol Drugs 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940054534 ophthalmic solution Drugs 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 5
- BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 description 5
- 230000002688 persistence Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- BDVFVCGFMNCYPV-NSHDSACASA-N 1-(5-isoquinolinesulfonyl)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1S(=O)(=O)C1=CC=CC2=CN=CC=C12 BDVFVCGFMNCYPV-NSHDSACASA-N 0.000 description 2
- CKFHAVRPVZNMGT-YQFADDPSSA-N 4-[(1r)-1-aminoethyl]-n-(1h-pyrrolo[2,3-b]pyridin-4-yl)benzamide;dihydrochloride Chemical compound Cl.Cl.C1=CC([C@H](N)C)=CC=C1C(=O)NC1=CC=NC2=C1C=CN2 CKFHAVRPVZNMGT-YQFADDPSSA-N 0.000 description 2
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000219 Sympatholytic Substances 0.000 description 2
- IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical compound C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- PRGUDWLMFLCODA-UHFFFAOYSA-N oxybuprocaine hydrochloride Chemical compound [Cl-].CCCCOC1=CC(C(=O)OCC[NH+](CC)CC)=CC=C1N PRGUDWLMFLCODA-UHFFFAOYSA-N 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001585 trabecular meshwork Anatomy 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- SPDDHUODLWQPBT-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-(1h-indazol-5-yl)-6,7-dimethoxyquinazolin-4-amine Chemical compound N=1C(NC=2C=C3C=NNC3=CC=2)=C2C=C(OC)C(OC)=CC2=NC=1C1=CC=C(F)C=C1 SPDDHUODLWQPBT-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- AWDORCFLUJZUQS-UHFFFAOYSA-N 4-methyl-5-[(2-methyl-1,4-diazepan-1-yl)sulfonyl]isoquinoline Chemical compound CC1CNCCCN1S(=O)(=O)C1=CC=CC2=CN=CC(C)=C12 AWDORCFLUJZUQS-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 description 1
- 101710088411 Rho-associated protein kinase 1 Proteins 0.000 description 1
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 1
- 101710088493 Rho-associated protein kinase 2 Proteins 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000001326 acute closed-angle glaucoma Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229960002610 apraclonidine Drugs 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- UDSRUCAJZSIRHZ-UHFFFAOYSA-N benzamide dihydrochloride Chemical compound Cl.Cl.NC(=O)C1=CC=CC=C1.NC(=O)C1=CC=CC=C1 UDSRUCAJZSIRHZ-UHFFFAOYSA-N 0.000 description 1
- IUGQFMIATSVYLK-UHFFFAOYSA-N benzyl 2-(4-hydroxyphenyl)acetate Chemical compound C1=CC(O)=CC=C1CC(=O)OCC1=CC=CC=C1 IUGQFMIATSVYLK-UHFFFAOYSA-N 0.000 description 1
- 229960002470 bimatoprost Drugs 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960003612 bunazosin hydrochloride Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000005682 chronic closed-angle glaucoma Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 201000004147 hypersecretion glaucoma Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- GURWIHFJWAKPGX-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-1h-indazol-5-amine Chemical compound C1CC(NC=2C=C3C=NNC3=CC=2)CCN1CC1=CC=CC=C1 GURWIHFJWAKPGX-UHFFFAOYSA-N 0.000 description 1
- DPAPGNJIIHRZFH-UHFFFAOYSA-N n-(1-benzylpyrrolidin-3-yl)-1h-indazol-5-amine Chemical compound C1CC(NC=2C=C3C=NNC3=CC=2)CN1CC1=CC=CC=C1 DPAPGNJIIHRZFH-UHFFFAOYSA-N 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000006366 primary open angle glaucoma Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 108010041788 rho-Associated Kinases Proteins 0.000 description 1
- 102000000568 rho-Associated Kinases Human genes 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000000948 sympatholitic effect Effects 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- 229940084765 timolol ophthalmic solution Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- 229950008081 unoprostone isopropyl Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a therapeutic agent for glaucoma comprising the combination of a Rho kinase inhibitor and a ⁇ -Blocker.
- Glaucoma is an intractable ocular disease with a risk of blindness, involving the increase of intraocular pressure due to various factors and the disorder of internal tissues of eyeballs (retina, an optic nerve and the like).
- a general method of treating glaucoma is intraocular pressure reduction therapy, which is exemplified by pharmacotherapy, laser therapy, surgical therapy and the like.
- drugs such as sympathomimetic agents (nonselective stimulants such as epinephrine, ⁇ 2 stimulants such as apraclonidine), sympatholytic agents ( ⁇ -blockers such as timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol and metipranolol and ⁇ 1 -blockers such as bunazosin hydrochloride), parasympathomimetic agents (pilocarpine and the like), carbonic anhydrase inhibitors (acetazolamide and the like) and prostaglandins (isopropyl unoprostone, latanoprost, travoprost, bimatoprost and the like) have been used.
- sympathomimetic agents nonselective stimulants such as epinephrine, ⁇ 2 stimulants such as apraclonidine
- Rho kinase inhibitor was found to serve as a therapeutic agent for glaucoma based on a new mechanism of action (WO 00/09162).
- Invest. Ophthalmol. & Vis. Sci., 42 (1), 137-144 (2001) discloses that the Rho kinase inhibitor increases the aqueous humor outflow from a trabecular meshwork outflow pathway thereby reducing intraocular pressure, and Invest. Ophthalmol. & Vis. Sci., 42 (1), 137-144 (2001) and Invest. Ophthalmol. & Vis. Sci., 42 (5), 1029-1037 (2001) suggest that the action is due to a change of cytoskeleton in trabecular meshwork cells.
- Combined use of drugs having actions of reducing intraocular pressure to treat glaucoma has already been studied and there are some reports on the studies.
- Japanese Patent No. 2726672 reports combined administration of the sympatholytic agent with prostaglandins.
- WO 02/38158 discloses a method of treating glaucoma by administering some drugs having actions of reducing intraocular pressure in combination to eyes.
- Rho kinase inhibitor Studying precisely effects due to the combination of a Rho kinase inhibitor and a ⁇ -blocker, the present inventors found that an action of reducing intraocular pressure is increased and/or persistence of the action is improved by combining these drugs compared with a case where each drug is used alone and consequently completed the present invention. Detailed test methods and their effects are described later under the item of “Pharmacological Tests”. A remarkable increase in action of reducing intraocular pressure and/or remarkable improvement of persistence of the action was observed by combining a Rho kinase inhibitor with a ⁇ -blocker.
- the present invention can be suitably used for treating and preventing ophthalmopathy accompanied by a rise of intraocular pressure.
- the increase in the action of reducing intraocular pressure and/or persistence of the action is improved by administering the combination of the Rho kinase inhibitor and the ⁇ -blocker to eyes. Accordingly, the present invention is useful as a therapeutic agent for glaucoma.
- the present invention relates to a therapeutic agent for glaucoma comprising the combination of a Rho kinase inhibitor and a ⁇ -blocker. These drugs complement and/or enhance their actions each other.
- each of the Rho kinase inhibitor and the ⁇ -blocker can be in a separate preparation and these drugs can be administered in combination.
- these drugs can be formulated in a single preparation to be administered. In other words, these drugs can be administered in mixture.
- Rho kinase inhibitors and the ⁇ -blockers of the present invention include salts thereof.
- these compounds can be salts with an inorganic acid such as hydrochloric acid or nitric acid or with an organic acid with oxalic acid, succinic acid, acetic acid or maleic acid.
- an acidic group such as a carboxyl group
- they can be salts with an alkali metal such as sodium or potassium or with an alkaline earth metal such as calcium.
- Rho kinase inhibitors and the ⁇ -blockers of the present invention include derivatives thereof such as esters.
- esters are alkyl esters such as methyl esters, ethyl esters and isopropyl esters.
- Rho kinase inhibitors and the ⁇ -blockers of the present invention can be in the form of hydrates or solvates.
- the present invention is characterized by treating glaucoma with the combination of a Rho kinase inhibitor and a ⁇ -blocker.
- Rho kinase inhibitor in the present invention means a compound which inhibits serine/threonine kinase activated with activation of Rho.
- examples of such compounds are the compounds which inhibit ROK ⁇ (ROCK-II), p160ROCK (ROK ⁇ , ROCK-I) and other compounds which inhibit proteins having a serine/threonine kinase activity.
- Rho kinase inhibitors such as (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide and (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)-benzamide disclosed in WO 98/06433 and WO 00/09162, Rho kinase inhibitors such as 1-(5-isoquinolinesulfonyl)homopiperazine and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine disclosed in WO 97/23222 and Nature, 389, 990-994 (1997), Rho kinase inhibitors such as (1-benzylpyrrolidin-4-yl)-(1H-indazol-5-yl)amine disclosed in WO 01/56988
- any ⁇ -blockers having the action of reducing intraocular pressure and utility in treating glaucoma can be used.
- ⁇ -Blockers having the action of reducing intraocular pressure are specifically exemplified by timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol and metipranolol, which have already been on the market as a therapeutic agent of glaucoma. These are preferably used.
- Glaucoma in the present invention includes primary open angle glaucoma, normal intraocular tension glaucoma, hypersecretion glaucoma, ocular hypertension, acute angle-closure glaucoma, chronic closed angle glaucoma, combined-mechanism glaucoma, corticosteroid glaucoma, amyloid glaucoma, neovascular glaucoma, malignant glaucoma, capsular glaucoma, plateau iris syndrome and the like.
- preparations can be two preparations prepared by formulating a Rho kinase inhibitor and a ⁇ -blocker separately or one preparation prepared by mixing these ingredients. Particular techniques are unnecessary for the formulation, and the preparations can be prepared using widely-used techniques.
- a preferred method of administration is eye topical administration, and a preferred dosage form is an ophthalmic solution or an eye ointment.
- each preparation can be prepared according to known methods.
- the Rho kinase inhibitor can be formulated in preparations by referring to Formulation Examples described in the above-mentioned International Publications (WO 00/09162 and WO 97/23222).
- the preparations of the ⁇ -blocker preparations of timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol, metipranolol and the like can be used. These preparations have already been on the market as the therapeutic agent of glaucoma.
- the formulation containing a Rho kinase inhibitor and a ⁇ -blocker in mixture can be also prepared according to known methods.
- the ophthalmic solutions can be prepared, using isotonic agents such as sodium chloride and concentrated glycerin; buffers such as sodium phosphate buffer and sodium acetate buffer; surfactants such as polyoxyethylene sorbitan monooleate, stearate polyoxyl 40, and polyoxyethylene hardened castor oil; stabilizers such as sodium citrate and sodium edetate; and preservatives such as benzalkonium chloride and paraben, as needed.
- isotonic agents such as sodium chloride and concentrated glycerin
- buffers such as sodium phosphate buffer and sodium acetate buffer
- surfactants such as polyoxyethylene sorbitan monooleate, stearate polyoxyl 40, and polyoxyethylene hardened castor oil
- stabilizers such as sodium citrate and sodium edetate
- preservatives such as benzalkon
- the pH should be within an ophthalmologically acceptable range and is preferably within a range from pH 4 to pH 8.
- a formulation example thereof is described below in the section of Example. However, the formulation example never limits the scope of the invention.
- the present invention also relates to a method of treating glaucoma comprising administering effective amounts of the Rho kinase inhibitor in combination with the ⁇ -blocker to a patient, By administering the effective amounts of the Rho kinase inhibitor in combination with the ⁇ -blocker to the patient, they complement and/or enhance their actions each other.
- Rho kinase inhibitors which are suitable for the method of treatment are (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin 4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinoline sulfonyl)homopiperazine and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.
- ⁇ -Blockers which are suitable for the method of treatment are timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol and metipranolol.
- the doses of a Rho kinase inhibitor and a ⁇ -blocker can be determined depending on the symptom and age of patients, the dosage form, the administration route and the like. The case of instillation is briefly described below.
- the dose of the Rho kinase inhibitor varies depending on the drug type.
- the Rho kinase inhibitor can be administered generally within a range from 0.025 to 10,000 ⁇ g daily from once to several times a day.
- the dose can be appropriately raised or lowered depending on the age and symptom of patients and the like.
- the dose of a ⁇ -blocker varies depending on drug type.
- the usual daily dose is within a range from 5 to 5,000 ⁇ g, which can be administered from once to several times a day. More specifically, timolol is generally administered at a daily dose of 5 to 1,500 ⁇ g, befunolol is administered at a daily dose of 10 to 2,000 ⁇ g, carteolol is administered at a daily dose of 10 to 5,000 ⁇ g, nipradilol is administered at a daily dose of 10 to 1,250 ⁇ g, betaxolol is administered at a daily dose of 50 to 1,000 ⁇ g, levobunolol is administered at a daily dose of 5 to 5,000 ⁇ g, and metipranolol is administered at a daily dose of 5 to 5,000 ⁇ g.
- the doses can be varied. Based on similar standards, the doses of the other ⁇ -blockers can be determined.
- Rho kinase inhibitor and a ⁇ -blocker are also applicable to the administration of the combination of a Rho kinase inhibitor and a ⁇ -blocker.
- the formulation should be prepared by selecting the mixing ratio of two drugs appropriately so that their daily doses might not excess each dose of the separate drugs.
- the mixed formulation can be administered from once to several times daily.
- FIG. 1 is a graph showing changes of intraocular pressure with time in respective administration groups.
- a general formulation example of an ophthalmic solution comprising a Rho kinase inhibitor ((R)-(+)-N-(1H-pyrrolo[2,3-b]-pyridin-4-yl)-4-(1-aminoethyl)benzamide dihydrochloride) and a ⁇ -blocker (timolol) in the present invention is shown below.
- Ophthalmic solution in 100 mL) (R)-(+)-N-(1H-Pyrrolo[2,3-b]pyridin-4-yl)-4-(1- 0.1 g aminoethyl)benzamide dihydrochloride Timolol maleate 0.34 g Boric acid 0.2 g Concentrated glycerin 0.25 g Benzalkonium chloride 0.005 g Diluted hydrochloric acid quantum sufficient Sodium hydroxide quantum sufficient Purified water quantum sufficient
- Ophthalmic solutions having desired combinations and desired concentrations can be prepared by changing the kinds and amounts of a Rho kinase inhibitor and a ⁇ -blocker and by appropriately changing the amounts of the additives.
- Rho kinase inhibitor So as to study the utility of the combination of a Rho kinase inhibitor and a ⁇ -blocker, they were administered to experimental animals, examining the effect on reducing intraocular pressure.
- (R)-(+)-N-(1H-Pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide dihydrochloride [Compound A] was used as the Rho kinase inhibitor.
- Timolol was used as the ⁇ -blocker.
- Rho kinase inhibitor was dissolved in physiological saline, and then sodium hydroxide was added to the solution to neutralize it (pH 6.0 to 7.0) to thereby prepare Rho kinase inhibitor solutions having desired concentrations.
- ⁇ -blocker ophthalmic solution was used as it was, or was diluted with physiological saline to prepare ⁇ -blocker solutions having desired concentrations.
- Rho kinase inhibitor solution 0.1% compound A solution (instillation dosage: 50 ⁇ l)
- ⁇ -Blocker solution Timolol ophthalmic solution (trade name: Timoptol 0.25%, instillation dosage: 50 ⁇ l)
- Experimental animal Japanese white rabbit (strain: JW, sex: male, four rabbits per group)
- Intraocular pressure is expressed in each change from initial intraocular pressure.
- the Rho kinase inhibitor and ⁇ -blocker combination group exhibited an excellent action of reducing intraocular pressure compared with single administration groups of each drug, namely the single administration group of the Rho kinase inhibitor and the single administration group of the ⁇ -blocker, and exhibited improvement of persistence of the action.
- the present invention provides a therapeutic agent for glaucoma comprising the combination of a Rho kinase inhibitor and a ⁇ -blocker.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A therapeutic agent for glaucoma including a combination of pharmaceutically effective amounts of a Rho kinase inhibitor and a β-blocker, wherein the Rho kinase inhibitor is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and the β-blocker is befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol. A method of treating glaucoma including administering effective amounts of a Rho kinase inhibitor and a β-blocker to a patient, wherein the Rho kinase inhibitor is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and the β-blocker is befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol.
Description
- This application is a continuation application of application Ser. No. 10/535,000, which is a United States national phase application under 35 USC 371 of International application PCT/JP2003/14559 filed Nov. 17, 2003. The entire contents of each of application Ser. No. 10/535,000 and International application PCT/JP2003/14559 are hereby incorporated by reference herein.
- The present invention relates to a therapeutic agent for glaucoma comprising the combination of a Rho kinase inhibitor and a β-Blocker.
- Glaucoma is an intractable ocular disease with a risk of blindness, involving the increase of intraocular pressure due to various factors and the disorder of internal tissues of eyeballs (retina, an optic nerve and the like). A general method of treating glaucoma is intraocular pressure reduction therapy, which is exemplified by pharmacotherapy, laser therapy, surgical therapy and the like.
- For the pharmacotherapy, drugs such as sympathomimetic agents (nonselective stimulants such as epinephrine, α2 stimulants such as apraclonidine), sympatholytic agents (β-blockers such as timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol and metipranolol and α1-blockers such as bunazosin hydrochloride), parasympathomimetic agents (pilocarpine and the like), carbonic anhydrase inhibitors (acetazolamide and the like) and prostaglandins (isopropyl unoprostone, latanoprost, travoprost, bimatoprost and the like) have been used.
- Recently, a Rho kinase inhibitor was found to serve as a therapeutic agent for glaucoma based on a new mechanism of action (WO 00/09162). Invest. Ophthalmol. & Vis. Sci., 42 (1), 137-144 (2001) discloses that the Rho kinase inhibitor increases the aqueous humor outflow from a trabecular meshwork outflow pathway thereby reducing intraocular pressure, and Invest. Ophthalmol. & Vis. Sci., 42 (1), 137-144 (2001) and Invest. Ophthalmol. & Vis. Sci., 42 (5), 1029-1037 (2001) suggest that the action is due to a change of cytoskeleton in trabecular meshwork cells.
- Combined use of drugs having actions of reducing intraocular pressure to treat glaucoma has already been studied and there are some reports on the studies. For example, Japanese Patent No. 2726672 reports combined administration of the sympatholytic agent with prostaglandins. WO 02/38158 discloses a method of treating glaucoma by administering some drugs having actions of reducing intraocular pressure in combination to eyes.
- However, any reports do not describe the Rho kinase inhibitor at all, and naturally, there is no description concerning advantageous effects brought about by combining the Rho kinase inhibitor with a β-blocker, either.
- As mentioned above, neither study nor report has been made concerning therapeutic effects on glaucoma obtained by combining the Rho kinase inhibitor with the β-blocker, so far.
- It is a very interesting subject to find utility as a therapeutic agent for glaucoma due to a combination of a Rho kinase inhibitor and a β-blocker.
- Studying precisely effects due to the combination of a Rho kinase inhibitor and a β-blocker, the present inventors found that an action of reducing intraocular pressure is increased and/or persistence of the action is improved by combining these drugs compared with a case where each drug is used alone and consequently completed the present invention. Detailed test methods and their effects are described later under the item of “Pharmacological Tests”. A remarkable increase in action of reducing intraocular pressure and/or remarkable improvement of persistence of the action was observed by combining a Rho kinase inhibitor with a β-blocker. The present invention can be suitably used for treating and preventing ophthalmopathy accompanied by a rise of intraocular pressure.
- The increase in the action of reducing intraocular pressure and/or persistence of the action is improved by administering the combination of the Rho kinase inhibitor and the β-blocker to eyes. Accordingly, the present invention is useful as a therapeutic agent for glaucoma.
- The present invention relates to a therapeutic agent for glaucoma comprising the combination of a Rho kinase inhibitor and a β-blocker. These drugs complement and/or enhance their actions each other.
- For the method of administration, each of the Rho kinase inhibitor and the β-blocker can be in a separate preparation and these drugs can be administered in combination. Alternatively, these drugs can be formulated in a single preparation to be administered. In other words, these drugs can be administered in mixture.
- The Rho kinase inhibitors and the β-blockers of the present invention include salts thereof. When these compounds have a basic group such as an amino group, they can be salts with an inorganic acid such as hydrochloric acid or nitric acid or with an organic acid with oxalic acid, succinic acid, acetic acid or maleic acid. When they have an acidic group such as a carboxyl group, they can be salts with an alkali metal such as sodium or potassium or with an alkaline earth metal such as calcium.
- The Rho kinase inhibitors and the β-blockers of the present invention include derivatives thereof such as esters. Specific examples of esters are alkyl esters such as methyl esters, ethyl esters and isopropyl esters.
- Further, the Rho kinase inhibitors and the β-blockers of the present invention can be in the form of hydrates or solvates.
- The present invention is characterized by treating glaucoma with the combination of a Rho kinase inhibitor and a β-blocker.
- The Rho kinase inhibitor in the present invention means a compound which inhibits serine/threonine kinase activated with activation of Rho. Examples of such compounds are the compounds which inhibit ROK α (ROCK-II), p160ROCK (ROK β, ROCK-I) and other compounds which inhibit proteins having a serine/threonine kinase activity. Specific Rho kinase inhibitors are exemplified by Rho kinase inhibitors such as (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide and (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)-benzamide disclosed in WO 98/06433 and WO 00/09162, Rho kinase inhibitors such as 1-(5-isoquinolinesulfonyl)homopiperazine and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine disclosed in WO 97/23222 and Nature, 389, 990-994 (1997), Rho kinase inhibitors such as (1-benzylpyrrolidin-4-yl)-(1H-indazol-5-yl)amine disclosed in WO 01/56988, Rho kinase inhibitors such as (1-benzylpiperidin-4-yl)-(1H-indazol-5-yl)amine disclosed in WO 02/100833, Rho kinase inhibitors such as N-[2-(4-fluorophenyl)-6,7-dimethoxy-4-quinazolinyl]-N-(1H-indazol-5-yl)amine disclosed in WO 02/076976, Rho kinase inhibitors such as N-4-(1H-indazol-5-yl)-6,7-dimethoxy-N-2-pyridin-4-yl-quinazolin-2,4-diamine disclosed in WO 02/076977 and Rho kinase inhibitors such as 4-methyl-5-(2-methyl-[1,4]diazepan-1-sulfonyl) isoquinoline disclosed in WO 99/64011.
- On the other hand, any β-blockers having the action of reducing intraocular pressure and utility in treating glaucoma can be used. β-Blockers having the action of reducing intraocular pressure are specifically exemplified by timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol and metipranolol, which have already been on the market as a therapeutic agent of glaucoma. These are preferably used.
- Glaucoma in the present invention includes primary open angle glaucoma, normal intraocular tension glaucoma, hypersecretion glaucoma, ocular hypertension, acute angle-closure glaucoma, chronic closed angle glaucoma, combined-mechanism glaucoma, corticosteroid glaucoma, amyloid glaucoma, neovascular glaucoma, malignant glaucoma, capsular glaucoma, plateau iris syndrome and the like.
- To carry out the present invention, preparations can be two preparations prepared by formulating a Rho kinase inhibitor and a β-blocker separately or one preparation prepared by mixing these ingredients. Particular techniques are unnecessary for the formulation, and the preparations can be prepared using widely-used techniques. A preferred method of administration is eye topical administration, and a preferred dosage form is an ophthalmic solution or an eye ointment.
- When a Rho kinase inhibitor and a β-blocker are formulated in preparations separately, each preparation can be prepared according to known methods. For example, the Rho kinase inhibitor can be formulated in preparations by referring to Formulation Examples described in the above-mentioned International Publications (WO 00/09162 and WO 97/23222). As the preparations of the β-blocker, preparations of timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol, metipranolol and the like can be used. These preparations have already been on the market as the therapeutic agent of glaucoma.
- The formulation containing a Rho kinase inhibitor and a β-blocker in mixture can be also prepared according to known methods. The ophthalmic solutions can be prepared, using isotonic agents such as sodium chloride and concentrated glycerin; buffers such as sodium phosphate buffer and sodium acetate buffer; surfactants such as polyoxyethylene sorbitan monooleate, stearate polyoxyl 40, and polyoxyethylene hardened castor oil; stabilizers such as sodium citrate and sodium edetate; and preservatives such as benzalkonium chloride and paraben, as needed.
- The pH should be within an ophthalmologically acceptable range and is preferably within a range from
pH 4 topH 8. For reference, a formulation example thereof is described below in the section of Example. However, the formulation example never limits the scope of the invention. - The present invention also relates to a method of treating glaucoma comprising administering effective amounts of the Rho kinase inhibitor in combination with the β-blocker to a patient, By administering the effective amounts of the Rho kinase inhibitor in combination with the β-blocker to the patient, they complement and/or enhance their actions each other. Rho kinase inhibitors which are suitable for the method of treatment are (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin 4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinoline sulfonyl)homopiperazine and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine. β-Blockers which are suitable for the method of treatment are timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol and metipranolol.
- The doses of a Rho kinase inhibitor and a β-blocker can be determined depending on the symptom and age of patients, the dosage form, the administration route and the like. The case of instillation is briefly described below. The dose of the Rho kinase inhibitor varies depending on the drug type. The Rho kinase inhibitor can be administered generally within a range from 0.025 to 10,000 μg daily from once to several times a day. The dose can be appropriately raised or lowered depending on the age and symptom of patients and the like.
- The dose of a β-blocker varies depending on drug type. The usual daily dose is within a range from 5 to 5,000 μg, which can be administered from once to several times a day. More specifically, timolol is generally administered at a daily dose of 5 to 1,500 μg, befunolol is administered at a daily dose of 10 to 2,000 μg, carteolol is administered at a daily dose of 10 to 5,000 μg, nipradilol is administered at a daily dose of 10 to 1,250 μg, betaxolol is administered at a daily dose of 50 to 1,000 μg, levobunolol is administered at a daily dose of 5 to 5,000 μg, and metipranolol is administered at a daily dose of 5 to 5,000 μg. Depending on the age, symptoms and the like of patients, the doses can be varied. Based on similar standards, the doses of the other β-blockers can be determined.
- These doses are also applicable to the administration of the combination of a Rho kinase inhibitor and a β-blocker. In case that a Rho kinase inhibitor and a β-blocker are to be administrated in one formulation, the formulation should be prepared by selecting the mixing ratio of two drugs appropriately so that their daily doses might not excess each dose of the separate drugs. The mixed formulation can be administered from once to several times daily.
-
FIG. 1 is a graph showing changes of intraocular pressure with time in respective administration groups. - A formulation example and pharmacological tests are shown in the following Examples. The Examples are for better understanding of the invention but never limits the scope of the invention.
- A general formulation example of an ophthalmic solution comprising a Rho kinase inhibitor ((R)-(+)-N-(1H-pyrrolo[2,3-b]-pyridin-4-yl)-4-(1-aminoethyl)benzamide dihydrochloride) and a β-blocker (timolol) in the present invention is shown below.
-
Ophthalmic solution (in 100 mL) (R)-(+)-N-(1H-Pyrrolo[2,3-b]pyridin-4-yl)-4-(1- 0.1 g aminoethyl)benzamide dihydrochloride Timolol maleate 0.34 g Boric acid 0.2 g Concentrated glycerin 0.25 g Benzalkonium chloride 0.005 g Diluted hydrochloric acid quantum sufficient Sodium hydroxide quantum sufficient Purified water quantum sufficient - Ophthalmic solutions having desired combinations and desired concentrations can be prepared by changing the kinds and amounts of a Rho kinase inhibitor and a β-blocker and by appropriately changing the amounts of the additives.
- So as to study the utility of the combination of a Rho kinase inhibitor and a β-blocker, they were administered to experimental animals, examining the effect on reducing intraocular pressure. (R)-(+)-N-(1H-Pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide dihydrochloride [Compound A] was used as the Rho kinase inhibitor. Timolol was used as the β-blocker.
- The Rho kinase inhibitor was dissolved in physiological saline, and then sodium hydroxide was added to the solution to neutralize it (pH 6.0 to 7.0) to thereby prepare Rho kinase inhibitor solutions having desired concentrations.
- A commercially available β-blocker ophthalmic solution was used as it was, or was diluted with physiological saline to prepare β-blocker solutions having desired concentrations.
- Administering the combination of the Rho kinase inhibitor and the β-blocker, the effect on reducing intraocular pressure was studied. As a reference, administering the Rho kinase inhibitor alone or the β-blocker alone, the effect on reducing intraocular pressure was also studied. As a control, only a vehicle (physiological saline) was administered.
- Rho kinase inhibitor solution: 0.1% compound A solution (instillation dosage: 50 μl)
β-Blocker solution: Timolol ophthalmic solution (trade name: Timoptol 0.25%, instillation dosage: 50 μl)
Experimental animal: Japanese white rabbit (strain: JW, sex: male, four rabbits per group) - 1) One drop of a 0.4% oxybuprocaine hydrochloride ophthalmic solution (trade name: Benoxil solution 0.4%) was instilled into both eyes of each experimental animal to anesthetize it topically.
2) Intraocular pressure was measured immediately before administering the test compound solution, and the intraocular pressure was referred to as initial intraocular pressure.
3) The Rho kinase inhibitor solution was instilled into one eye of each experimental animal (the other eye was not treated). Since it is impossible to instill the β-blocker solution at the same time, after a short period (about five minutes), the β-blocker solution was instilled into the same eye.
4) One, two and four hours after instilling the Rho kinase inhibitor solution, one drop of the 0.4% oxybuprocaine hydrochloride ophthalmic solution was instilled into both eyes to anesthetize them topically. Then intraocular pressure was measured three times to obtain the average of three measurements. - Each test was carried out in the same manner as in the above-mentioned combination administration test except that the β-blocker solution was replaced with physiological saline.
- Each test was carried out in the same manner as in the above-mentioned combination administration test except that the Rho kinase inhibitor solution was replaced with physiological saline.
- Each test was carried out in the same manner as in the above-mentioned combination administration test except that the Rho kinase inhibitor solution and the β-blocker solution were replaced with physiological saline.
- Results of the tests are shown in
FIG. 1 . Intraocular pressure is expressed in each change from initial intraocular pressure. - As apparent from
FIG. 1 , the Rho kinase inhibitor and β-blocker combination group exhibited an excellent action of reducing intraocular pressure compared with single administration groups of each drug, namely the single administration group of the Rho kinase inhibitor and the single administration group of the β-blocker, and exhibited improvement of persistence of the action. - When combinations of the other Rho kinase inhibitors and the other β-blockers disclosed in the specification were tested, tendencies similar to the above-mentioned test results were also observed.
- The above-mentioned results show that a stronger reducing effect on intraocular pressure and/or improvement of persistence is obtained by combining the Rho kinase inhibitor with the β-blocker.
- The present invention provides a therapeutic agent for glaucoma comprising the combination of a Rho kinase inhibitor and a β-blocker.
Claims (2)
1. A therapeutic agent for glaucoma comprising a combination of pharmaceutically effective amounts of a Rho kinase inhibitor and a β-blocker, wherein the Rho kinase inhibitor is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and the β-blocker is befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol.
2. A method of treating glaucoma comprising administering effective amounts of a Rho kinase inhibitor and a β-blocker to a patient, wherein the Rho kinase inhibitor is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide and the β-blocker is befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/135,295 US20110263638A1 (en) | 2002-11-18 | 2011-06-30 | Therapeutic agent for glaucoma comprising rho kinase inhibitor and ß- blocker |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-333213 | 2002-11-18 | ||
JP2002333213 | 2002-11-18 | ||
PCT/JP2003/014559 WO2004045644A1 (en) | 2002-11-18 | 2003-11-17 | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND β-BLOCKER |
US10/535,000 US7972612B2 (en) | 2002-11-18 | 2003-11-17 | Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker |
US13/135,295 US20110263638A1 (en) | 2002-11-18 | 2011-06-30 | Therapeutic agent for glaucoma comprising rho kinase inhibitor and ß- blocker |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/535,000 Continuation US7972612B2 (en) | 2002-11-18 | 2003-11-17 | Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker |
PCT/JP2003/014559 Continuation WO2004045644A1 (en) | 2002-11-18 | 2003-11-17 | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND β-BLOCKER |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110263638A1 true US20110263638A1 (en) | 2011-10-27 |
Family
ID=32321688
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/535,000 Expired - Fee Related US7972612B2 (en) | 2002-11-18 | 2003-11-17 | Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker |
US13/135,295 Abandoned US20110263638A1 (en) | 2002-11-18 | 2011-06-30 | Therapeutic agent for glaucoma comprising rho kinase inhibitor and ß- blocker |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/535,000 Expired - Fee Related US7972612B2 (en) | 2002-11-18 | 2003-11-17 | Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker |
Country Status (9)
Country | Link |
---|---|
US (2) | US7972612B2 (en) |
EP (1) | EP1568382B1 (en) |
JP (2) | JP4314433B2 (en) |
KR (2) | KR101223886B1 (en) |
CN (1) | CN1323719C (en) |
AU (1) | AU2003280812A1 (en) |
CA (1) | CA2506464C (en) |
ES (1) | ES2444841T3 (en) |
WO (1) | WO2004045644A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110130388A1 (en) * | 2008-07-24 | 2011-06-02 | Yasushi Ikuno | Prophylactic or therapeutic agent for axial myopia |
US11446273B2 (en) | 2017-12-21 | 2022-09-20 | Santen Pharmaceutical Co., Ltd. | Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050245509A1 (en) * | 2002-08-29 | 2005-11-03 | Santen Pharmacecutical Co., Ltd. | Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins |
CA2506464C (en) * | 2002-11-18 | 2012-07-31 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for glaucoma comprising rho kinase inhibitor and .beta.-blocker |
JP2006348028A (en) * | 2005-05-19 | 2006-12-28 | Kowa Co | Prophylactic or curative agent for glaucoma |
KR101333970B1 (en) * | 2005-05-19 | 2013-11-27 | 코와 가부시키가이샤 | Preventing or treating agent for glaucoma |
EP1902731B1 (en) * | 2005-06-21 | 2013-04-10 | Kowa Company, Ltd. | Preventive or remedy for glaucoma |
EP1905452B1 (en) | 2005-07-12 | 2013-06-19 | Kowa Company, Ltd. | Agent for prevention or treatment of glaucoma |
JP5220414B2 (en) * | 2005-08-30 | 2013-06-26 | 旭化成ファーマ株式会社 | Sulfonamide compounds |
KR20090057223A (en) * | 2006-07-31 | 2009-06-04 | 센주 세이야꾸 가부시키가이샤 | Aqueous liquid preparation containing amide compound |
WO2008105058A1 (en) * | 2007-02-27 | 2008-09-04 | Asahi Kasei Pharma Corporation | Sulfonamides |
AU2008220104B2 (en) | 2007-02-28 | 2012-09-27 | Asahi Kasei Pharma Corporation | Sulfonamide derivative |
JP5234825B2 (en) | 2007-07-02 | 2013-07-10 | 旭化成ファーマ株式会社 | Sulfonamide compounds and crystals thereof |
US9339496B2 (en) | 2012-07-13 | 2016-05-17 | Santen Pharmaceutical Co., Ltd. | Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist |
WO2016093346A1 (en) * | 2014-12-12 | 2016-06-16 | 興和株式会社 | Aqueous composition |
US20200121652A1 (en) | 2017-06-16 | 2020-04-23 | The Doshisha | Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent |
AU2018283250B2 (en) | 2017-06-16 | 2022-09-01 | The Doshisha | mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
KR20200103041A (en) | 2017-12-21 | 2020-09-01 | 산텐 세이야꾸 가부시키가이샤 | Combination of Omidenepak |
IL311711A (en) * | 2021-09-30 | 2024-05-01 | Regeneron Pharma | Treatment of glaucoma with rho guanine nucleotide exchange factor 12 (arhgef12) inhibitors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5093126A (en) * | 1987-09-26 | 1992-03-03 | Alcon Laboratories, Inc. | Glaucoma formulations comprising an anionic, polysulfonic acid polymer having mucomimetic properties and a polystyrene sulfonic polymer |
WO2000009162A1 (en) * | 1998-08-17 | 2000-02-24 | Senju Pharmaceutical Co., Ltd. | Preventives/remedies for glaucoma |
US7972612B2 (en) * | 2002-11-18 | 2011-07-05 | Santen Pharmaceutical Co., Ltd. | Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601247A1 (en) | 1986-07-09 | 1988-01-15 | Merk Sharp Dohme Chibret Labor | COMBINATION OF BETA-BLOCKING AGENTS AND PILOCARPINE. |
US4952581A (en) | 1987-04-03 | 1990-08-28 | The Trustees Of Columbia University In The City Of New York | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure |
ES2042625T5 (en) | 1987-04-03 | 2000-07-16 | Univ Columbia | USE OF A PROSTAGLANDINE IN COMBINATION WITH AN ADRENERGIC BLOCKING AGENT FOR THE REDUCTION OF INTRAOCULAR PRESSURE. |
ES2052735T3 (en) | 1987-09-18 | 1994-07-16 | R Tech Ueno Ltd | A METHOD FOR PRODUCING AN EYE HYPOTENSION AGENT. |
CA1334168C (en) * | 1988-04-26 | 1995-01-31 | Louis M. De Santis | Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers |
ES2213504T1 (en) | 1988-09-06 | 2004-09-01 | Pfizer Health Ab | PROSTAGLANDIN DERIVATIVES FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION. |
DK0625903T3 (en) * | 1992-02-21 | 1999-05-10 | Alcon Lab Inc | Topical anti-glaucoma preparations comprising carboxylic acid anhydrase inhibitors and beta-blockers |
CA2131101A1 (en) | 1992-05-13 | 1993-11-25 | Louis Desantis Jr. | Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents |
BR9306399A (en) * | 1992-05-22 | 1998-09-15 | Senju Pharma Co | Pharmaceutical composition for use in the treatment of glaucoma |
US5352708A (en) | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5510383A (en) | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
CN1155383C (en) | 1995-12-21 | 2004-06-30 | 阿尔康实验室公司 | Use of certain isoquinolinesulfonyl compounds for treatment of glaucoma and ocular ischemia |
EP0956865B2 (en) | 1996-08-12 | 2010-08-18 | Mitsubishi Tanabe Pharma Corporation | MEDICINES COMPRISING Rho KINASE INHIBITOR |
ES2314786T3 (en) * | 1998-04-02 | 2009-03-16 | Genentech, Inc. | USE OF INTERFERON GAMMA FOR THE TREATMENT OF CARDIAC HYPERTROPHY. |
SE9803761D0 (en) | 1998-11-04 | 1998-11-04 | Synphora Ab | Method to avoid increased iridial pigmentation during prostaglandin treatment |
AU3328600A (en) * | 1999-03-25 | 2000-10-16 | Santen Pharmaceutical Co. Ltd. | Ocular tension-lowering agents |
US20030018079A1 (en) * | 2000-11-13 | 2003-01-23 | Richardson Helene | Treatment |
IL162475A0 (en) | 2001-12-12 | 2005-11-20 | Pharmacia Corp | Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists |
JP4300347B2 (en) | 2002-01-29 | 2009-07-22 | 参天製薬株式会社 | Glaucoma treatment agent consisting of bunazosin and prostaglandins |
TW200305424A (en) | 2002-01-29 | 2003-11-01 | Santen Pharmaceutical Co Ltd | Glaucoma-treating agent comprising bunazosin and prostaglandin |
US20050245509A1 (en) | 2002-08-29 | 2005-11-03 | Santen Pharmacecutical Co., Ltd. | Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins |
US20040266755A1 (en) * | 2003-05-29 | 2004-12-30 | Schering Aktiengesellschaft | Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine |
-
2003
- 2003-11-17 CA CA2506464A patent/CA2506464C/en not_active Expired - Fee Related
- 2003-11-17 KR KR1020117007966A patent/KR101223886B1/en not_active IP Right Cessation
- 2003-11-17 US US10/535,000 patent/US7972612B2/en not_active Expired - Fee Related
- 2003-11-17 JP JP2003386138A patent/JP4314433B2/en not_active Expired - Fee Related
- 2003-11-17 CN CNB2003801034679A patent/CN1323719C/en not_active Expired - Fee Related
- 2003-11-17 ES ES03772800.3T patent/ES2444841T3/en not_active Expired - Lifetime
- 2003-11-17 AU AU2003280812A patent/AU2003280812A1/en not_active Abandoned
- 2003-11-17 EP EP03772800.3A patent/EP1568382B1/en not_active Expired - Lifetime
- 2003-11-17 WO PCT/JP2003/014559 patent/WO2004045644A1/en active Application Filing
- 2003-11-17 KR KR1020057008569A patent/KR101103141B1/en not_active IP Right Cessation
-
2008
- 2008-09-25 JP JP2008245694A patent/JP4934653B2/en not_active Expired - Fee Related
-
2011
- 2011-06-30 US US13/135,295 patent/US20110263638A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5093126A (en) * | 1987-09-26 | 1992-03-03 | Alcon Laboratories, Inc. | Glaucoma formulations comprising an anionic, polysulfonic acid polymer having mucomimetic properties and a polystyrene sulfonic polymer |
WO2000009162A1 (en) * | 1998-08-17 | 2000-02-24 | Senju Pharmaceutical Co., Ltd. | Preventives/remedies for glaucoma |
US6673812B1 (en) * | 1998-08-17 | 2004-01-06 | Senju Pharmaceutical Co., Ltd. | Preventives/remedies for glaucoma |
US7972612B2 (en) * | 2002-11-18 | 2011-07-05 | Santen Pharmaceutical Co., Ltd. | Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110130388A1 (en) * | 2008-07-24 | 2011-06-02 | Yasushi Ikuno | Prophylactic or therapeutic agent for axial myopia |
US11446273B2 (en) | 2017-12-21 | 2022-09-20 | Santen Pharmaceutical Co., Ltd. | Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor |
Also Published As
Publication number | Publication date |
---|---|
KR101223886B1 (en) | 2013-01-17 |
CA2506464C (en) | 2012-07-31 |
KR20110045101A (en) | 2011-05-03 |
CA2506464A1 (en) | 2004-06-03 |
AU2003280812A1 (en) | 2004-06-15 |
US20060052367A1 (en) | 2006-03-09 |
KR101103141B1 (en) | 2012-01-04 |
US7972612B2 (en) | 2011-07-05 |
CN1323719C (en) | 2007-07-04 |
EP1568382B1 (en) | 2013-11-06 |
KR20050075000A (en) | 2005-07-19 |
JP4934653B2 (en) | 2012-05-16 |
WO2004045644A1 (en) | 2004-06-03 |
EP1568382A1 (en) | 2005-08-31 |
JP2004182723A (en) | 2004-07-02 |
JP2009029828A (en) | 2009-02-12 |
JP4314433B2 (en) | 2009-08-19 |
ES2444841T3 (en) | 2014-02-27 |
CN1711107A (en) | 2005-12-21 |
EP1568382A4 (en) | 2007-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110263638A1 (en) | Therapeutic agent for glaucoma comprising rho kinase inhibitor and ß- blocker | |
CA2496797C (en) | Therapeutic agent for glaucoma comprising rho kinase inhibitor and prostaglandin | |
JP6383058B2 (en) | Combination of sulfonamide compounds | |
US11974994B2 (en) | Agent for treating or preventing glaucoma including a sulfonamide compound and another drug | |
JP4482726B2 (en) | Glaucoma treatment agent comprising Rho kinase inhibitor and prostaglandins | |
TW202126308A (en) | Drug therapy for preventing or treating glaucoma | |
US20140018350A1 (en) | Combination of sulfonamide compound and tafluprost | |
WO2019131901A1 (en) | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | |
JP2012250952A (en) | COMBINATION OF ADENOSINE DERIVATIVE AND Rho KINASE INHIBITOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SANTEN PHARMACEUTICAL CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HATANO, MASAKAZU;NAKAJIMA, TADASHI;MATSUGI, TAKESHI;AND OTHERS;REEL/FRAME:026619/0673 Effective date: 20050218 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |